BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Market Outperform” Rating from JMP Securities
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a research report issued on Friday,Benzinga reports. They presently have a $18.00 price target on the biotechnology company’s stock. JMP Securities’ price objective would indicate a potential upside of 127.13% from the company’s current […]
More Stories
The Role of Vitamin A in Measles Management
By George Citroner A school-aged child in Texas recently became the first fatality in a rapidly spreading measles outbreak that...
Bessent ‘Slightly Shocked’ by Scale of Fraud Uncovered by DOGE
By Tom Ozimek Treasury Secretary Scott Bessent said Friday that the Department of Government Efficiency (DOGE) is making significant strides...
Russians React to Trump’s Peace Overtures With Cautious Optimism
By Adam Morrow President Donald Trump returned to the White House last month vowing to end the war between Russia...
Social Security Administration Says It Plans to Lay Off 7,000 Workers
By Aldgra Fredly The Social Security Administration (SSA) said on Friday that it is planning to lay off about 20...
Around 3,000 More US Troops Deploying to Southern Border
By Ryan Morgan Around 3,000 additional U.S. troops are set to deploy to the U.S. southern border in the next...
Guterres urges parties to find a way forward on next phase of Gaza ceasefire
As the first phase of the Gaza ceasefire and hostage release deal concludes, UN Secretary-General António Guterres is closely following...